Table 1.
Baseline characteristics among patients with HER2+ mBC with ≥1 line of therapya
| All patients with at least 1L N = 2074 |
Patients with HR+mBC and at least 1L N = 1303 |
Patients with HR− mBC and at least 1L N = 720 |
|
|---|---|---|---|
| Age (years) at start of 1L | |||
| Median (range) | 61 (24-84) | 61 (25-84) | 60 (24-83) |
| Age (years) at initial BC diagnosis | |||
| Median (range) | 58 (23-83) | 57 (23-83) | 58 (24-83) |
| Sex | |||
| Male | 20 (1.0%) | 18 (1.4%) | 2 (0.3%) |
| Female | 2054 (99.0%) | 1285 (98.6%) | 718 (99.7%) |
| Race | |||
| White | 1301 (62.7%) | 826 (63.4%) | 441 (61.3%) |
| Black or African American | 246 (11.9%) | 141 (10.8%) | 100 (13.9%) |
| Asian | 65 (3.1%) | 42 (3.2%) | 20 (2.8%) |
| Other | 288 (13.9%) | 179 (13.7%) | 103 (14.3%) |
| Unknown | 174 (8.4%) | 115 (8.8%) | 56 (7.8%) |
| Time (days) from initial BC diagnosis to start of 1L | |||
| Number of observations | 2073 | 1302 | 720 |
| Mean (SD) | 1058 (1,615) | 1180 (1,746) | 837 (1,290) |
| Median (range) | 411 (0-15,520) | 491 (1-15,520) | 298 (0-10,720) |
| Stage at initial breast cancer diagnosis | |||
| I | 183 (8.8%) | 109 (8.4%) | 67 (9.3%) |
| II | 435 (21.0%) | 313 (24.0%) | 116 (16.1%) |
| III | 425 (20.5%) | 248 (19.0%) | 166 (23.1%) |
| IV | 891 (43.0%) | 546 (41.9%) | 321 (44.6%) |
| Unknown | 140 (6.8%) | 87 (6.7%) | 50 (6.9%) |
| Number of metastatic sites at any time prior to or at start of 1L | |||
| 1 | 867 (41.8%) | 552 (42.4%) | 290 (40.3%) |
| 2 | 534 (25.7%) | 333 (25.6%) | 188 (26.1%) |
| 3 | 306 (14.8%) | 191 (14.7%) | 109 (15.1%) |
| 4+ | 212 (10.2%) | 132 (10.1%) | 75 (10.4%) |
| Unknown | 155 (7.5%) | 95 (7.3%) | 58 (8.1%) |
| Sites of metastases at any time prior to or at start of 1L | |||
| Bone | 1068 (51.5%) | 746 (57.3%) | 297 (41.3%) |
| Brain | 191 (9.2%) | 96 (7.4%) | 89 (12.4%) |
| Liver | 689 (33.2%) | 405 (31.1%) | 266 (36.9%) |
| Lung | 650 (31.3%) | 382 (29.3%) | 254 (35.3%) |
Cell entries show n (%), unless otherwise specified.
aFifteen one patients had missing HR status.
Abbreviations: 1L = first-line therapy; BC = breast cancer; HER2+ = human epidermal growth factor receptor 2 positive; HR = hormone receptor; HR- = hormone receptor negative; HR+ = hormone receptor positive; mBC = metastatic breast cancer; SD = standard deviation.